| Keywords: |
mitogen activated protein kinase; protein kinase b; gene mutation; nonhuman; colorectal cancer; cell proliferation; apoptosis; editorial; drug effect; phosphatidylinositol 3 kinase; colorectal carcinoma; lung adenocarcinoma; breast carcinoma; drug response; carcinogenicity; gene fusion; cell migration; chromosome rearrangement; ras protein; lymphatic leukemia; malignant transformation; salivary gland carcinoma; transcription factor etv6; brain derived neurotrophic factor receptor; molecularly targeted therapy; protein tyrosine kinase a; neurotrophin 3 receptor; pi3k/akt signaling; mapk signaling; human; entrectinib; malignant neoplasm; ntrk3 gene; solid malignant neoplasm; larotrectinib; ntrk1 gene; ntrk2 gene; etv6 gene; 2,3 dihydro 2 oxo 3 (4,5,6,7 tetrahydro 1h indol 2 ylmethylene) 1h indole 5 sulfonic acid dimethylamide; congenital infantile fibrosarcoma
|
